Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03984799 · ClinicalTrials.gov registry record · NA

Interleukin-5 Receptor Expression in COPD

A NA study of COPD, sponsored by University of Virginia.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT03984799 is a NA study of COPD that has completed, run by University of Virginia. The registered enrollment target is 20 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03984799, a NA study of COPD, has completed, sponsored by University of Virginia.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

At visit one, after the subject has signed the consent form, subjects will answer questions and have maximum reversibility lung function test to determine if they are eligible to proceed with the study. Once the study team has proven that the subject is eligible to proceed the study team will collect a sputum sample and blood sample to study their cells. At visit two the subjects will undergo a research bronchoscopy at this point the study team will collect more samples including a BAL sample and another blood sample. Three follow up phone calls will be conducted after the procedure to ensure subject safety, the study team will record any symptoms that they are experiencing at that time. Throughout this study the samples will be analyzed to see if a larger subset of COPD patients could benefit from using the drug mepolizumab.

Conditions Studied

Interventions

  • PROCEDURE Bronchoscopy

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2020-02-21
Est. Completion 2022-04-30
Phase NA

Sponsor

University of Virginia

449 total trials

What the Registry Record Tells You About NCT03984799

The ClinicalTrials.gov registry entry for NCT03984799 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (99% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 1 intervention - of which Bronchoscopy is the first listed.

NCT03984799 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT03984799 about?

NCT03984799 is a clinical study titled "Interleukin-5 Receptor Expression in COPD". At visit one, after the subject has signed the consent form, subjects will answer questions and have maximum reversibility lung function test to determine if they are eligible to proceed with the study. Once the study team has proven that the subject is eligible to proceed the study team will collec...

What is the current status of trial NCT03984799?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2020-02-21. Estimated completion is 2022-04-30.

What conditions does trial NCT03984799 study?

This clinical trial studies the following conditions: COPD.

What interventions are being tested in trial NCT03984799?

The interventions under investigation include: Bronchoscopy (PROCEDURE).

Who is sponsoring clinical trial NCT03984799?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03984799 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.